Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 28, 2024 06:59 ET | Source: Pasithea

Pasithea Therapeutics to Present New Preclinical Data Showing PAS-004 Strongly Inhibits NRAS Cancer Cell Lines and Demonstrates Superior Activity in Xenograft Studies at 2024 ASCO Annual Meeting

Pasithea to present preclinical data at ASCO 2024 showing PAS-004 superior inhibition of NRAS cancer cells and xenograft tumors compared to current MEKi's
January 02, 2024 05:33 ET | Source: Research and Markets

TAFINLAR + MEKINIST Drug Insight and Market Outlook to 2032 in Glioblastoma Multiforme Treatment Scenario

Dublin, Jan. 02, 2024 (GLOBE NEWSWIRE) -- The "TAFINLAR + MEKINIST Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. The report delves deep into...
July 31, 2023 05:33 ET | Source: Research and Markets

Global Thyroid Cancer Drugs Market to Reach $1.29 Billion by 2027: Targeted Therapies Transforming Thyroid Cancer Treatment

Dublin, July 31, 2023 (GLOBE NEWSWIRE) -- The "Thyroid Cancer Drugs Global Market Report 2023" has been added to ResearchAndMarkets.com's offering. This report provides a comprehensive guide to...
November 19, 2021 05:03 ET | Source: Research and Markets

Global MEK Inhibitors Market, Drug Sales & Clinical Trials to 2026: USD 3 Billion Market Opportunity

Dublin, Nov. 19, 2021 (GLOBE NEWSWIRE) -- The "Global MEK Inhibitors Market, Drug Sales & Clinical Trials insight 2026" report has been added to ResearchAndMarkets.com's offering. The advances...